Immune checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) pathways are among the newest entrants into the arsenal for cancer treatment [1]. Here, CTLA4 is linked to cancer.